Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

131.14 +0.95 (+0.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics

< Previous 1 2 3 4 5 6 7 Next >
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it. 
Via InvestorPlace
3 Up-and-Coming Growth Stocks to Buy Right Now
These companies are small now but could grow much larger over time. 
Via The Motley Fool
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
SRPT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sarepta Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
TD Cowen Maintains Outperform Rating for Sarepta Therapeutics: Here's What You Need To Know
 
Via Benzinga
The Latest Analyst Ratings for Sarepta Therapeutics
 
Via Benzinga
Sarepta Therapeutics' FDA Adcomm Puts Some Risk, With Potential Approval: Analyst
 
Via Benzinga
Accelerated Approval For Gene Therapies - US Health Regulator Looks To Improve Process
The FDA seeks to optimize the development of gene therapies to help get accelerated approval of therapies. The US health regulator is looking to encourage using biomarkers, such as pulse and blood... 
Via Benzinga
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Sarepta Therapeutics, Inc. (SRPT) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Why did Sarepta Therapeutics Stock Plummet?
SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating. 
Via MarketBeat
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Sarepta Crashes On An Unexpected Roadblock For Its Gene Therapy
The decision is an about-face from what Sarepta said roughly two weeks ago. 
Via Investor's Business Daily
Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review
A market rally is underway, but bank stocks kept tumbling. 
Via Investor's Business Daily
Why Baidu Shares Are Trading Higher By More Than 6%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Enzo Biochem, Inc. (NYSE: ENZ) gained 86.5% to $2.22 after the company announced it will sell its clinical laboratory to Labcorp. 
Via Benzinga
Sarepta Plunges As FDA Takes Surprise Turn; AdComm Meeting Set For Duchenne Gene Therapy
 
Via Benzinga
First Republic Bank, Blend Labs, Purple Innovation And Other Big Stocks Moving Lower On Friday
U.S. stocks traded lower, with the Dow Jones dropping more than 400 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why Are Crypto Stocks COIN, MARA, RIOT, HUT, MSTR Up Today?
Crypto stocks are on the rise Friday as traders celebrate another rally for Bitcoin (BTC) as it continues recent positive movement. 
Via InvestorPlace
The 2 Stocks to Watch on a Nail-Biter Friday
Investors are preparing for a volatile day. 
Via The Motley Fool
NVDA Stock Price Prediction: Morgan Stanley Issues $304 Price Target for Nvidia Shares
Nvidia (NVDA) stock is on the move Friday as investors react to a new price target from Morgan Stanley analyst Joseph Moore. 
Via InvestorPlace
Why Is Sarepta Therapeutics (SRPT) Stock Down 20% Today?
Sarepta Therapeutics (SRPT) stock is sliding lower on Friday after the company announced an advisory committee meeting with the FDA. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
The biggest pre-market stock movers for Friday are ready to go as we dive into the latest news for investors this morning! 
Via InvestorPlace
Why Sarepta Therapeutics Shares Are Trading Lower By Around 19%; Here Are 20 Stocks Moving Premarket
Gainers Enzo Biochem, Inc. (NYSE: ENZ) shares rose 89.9% to $2.26 in pre-market trading after the company announced it will sell its clinical laboratory to Labcorp. 
Via Benzinga
Nasdaq, S&P Futures Dip, Signaling Pause In Rally As Focus Shifts To Next Week's Fed Decision: Analyst Says Brace For More Volatility Near Term
The mood on Wall Street continues to be jittery, with the major index futures trading marginally to modestly lower. The weak sentiment reflected apprehensions concerning how the banking crisis will... 
Via Benzinga
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT
From The Rosen Law Firm, P.A.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Sarepta Therapeutics Announces Advisory Committee Meeting will be Held for SRP-9001
From Sarepta Therapeutics, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Meta Platforms To Rally 27%? Here Are 10 Other Analyst Forecasts For Thursday
Wells Fargo cut the price target for SVB Financial Group (NASDAQ: SIVB) from $350 to $300. Wells Fargo analyst Steven Shaw maintained an Overweight rating. SVB Financial shares fell 29.1% to $190.02 in... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.